Multiple c-Met inhibitors are currently under clinical investigation for hepatocellular carcinoma and some inhibitors, such as tepotinib, tivantinib, and capmatinib, show a promising therapeutic effect [31]. This evidence concerns the gene MET and hepatocellular carcinoma.